Last Updated on January 25, 2020 by HepFree NYC
The NYC Department of Health and Mental Hygiene (DOHMH) examined anti-HCV and RNA testing performed by dialysis centres in NYC between 1 January 2014 and 31 December 2017 to assess HCV testing practices.
TAKE ACTION TO INCREASE SUPPORT FOR THIS IMPORTANT LEGISLATION!
Participants described psychological and behavioral transformation over the course of HCV treatment. These included reductions in internalized stigma and shame related to HCV and addiction, increases in HCV disclosure and self-care, reductions in substance use, and new desire to ...
Hep B Testing Health Code Amendment Adopted in NYC! In order to improve complete hepatitis B diagnostic testing, care and treatment rates in NYC at the population level, the NYC Board of Health adopted an amendment to the Health Code. The NYC Health Department will receive ne...
The NYC Health Department today released the City's first-ever plan for reducing illness and death from the hepatitis C virus (HCV), a disease that now accounts for more annual deaths nationwide than HIV/AIDS
We describe the mortality profile of NYC residents with HBV or HCV, emphasizing the contributions of HCC and HIV coinfection.
DAKLINZA is the first drug that has demonstrated safety and efficacy to treat genotype 3 HCV infections without the need for co-administration of interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.
As New York State enters this era of successful HCV treatment, the NYSDOH AIDS Institute has developed criteria for defining those providers qualified to manage and treat patients with HCV infection.
